These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36162055)

  • 21. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
    Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
    Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma.
    Shah AM; Guo L; Morales MG; Jaichander P; Chen K; Huang H; Cano Hernandez K; Xu L; Bassel-Duby R; Olson EN; Liu N
    Sci Adv; 2023 Apr; 9(17):eade8184. PubMed ID: 37115930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.
    Granados VA; Avirneni-Vadlamudi U; Dalal P; Scarborough SR; Galindo KA; Mahajan P; Galindo RL
    Cancer Res; 2019 Sep; 79(18):4585-4591. PubMed ID: 31331911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
    Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
    J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
    Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
    Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
    Kowalczyk JT; Wan X; Hernandez ER; Luo R; Lyons GC; Wilson KM; Gallardo DC; Isanogle KA; Robinson CM; Mendoza A; Heske CM; Chen JQ; Luo X; Kelly AE; Difilippantinio S; Robey RW; Thomas CJ; Sackett DL; Morrison DK; Randazzo PA; Jenkins LMM; Yohe ME
    Mol Cancer Ther; 2021 Feb; 20(2):307-319. PubMed ID: 33158997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
    Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H
    Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FAK Signaling in Rhabdomyosarcoma.
    Perrone C; Pomella S; Cassandri M; Braghini MR; Pezzella M; Locatelli F; Rota R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
    Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
    Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
    Ramadan F; Fahs A; Ghayad SE; Saab R
    Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
    Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
    Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma.
    Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J
    Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
    Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
    Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.
    Fan F; Ghosh S; Powell R; Roszik J; Park Y; Sobieski M; Sorokin A; Stephan C; Kopetz S; Ellis LM; Bhattacharya R
    PLoS One; 2023; 18(3):e0281063. PubMed ID: 36952536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.